INHBA is a mediator of aggressive tumor behavior in HER2+ basal breast cancer
Abstract Background Resistance to HER2-targeted therapeutics remains a significant clinical problem in HER2+ breast cancer patients with advanced disease.This may be particularly true for HER2+ patients with basal subtype disease, as recent evidence suggests they receive limited benefit from standard of care HER2-targeted therapies.Identification o